应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
OTLK Outlook Therapeutics, Inc.
盘后交易 02-18 17:00:13 EST
0.4096
-0.0127
-3.01%
盘后
0.4112
+0.0016
+0.39%
17:00 EST
最高
0.4266
最低
0.3900
成交量
125.80万
今开
0.4266
昨收
0.4223
日振幅
8.67%
总市值
3,011万
流通市值
2,383万
总股本
7,351万
成交额
51.02万
换手率
2.16%
流通股本
5,818万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
Outlook Therapeutics, Inc.盘中异动 股价大跌5.78%报0.462美元
市场透视 · 02-17 22:30
Outlook Therapeutics, Inc.盘中异动 股价大跌5.78%报0.462美元
Outlook Therapeutics Inc:拟继续与FDA合作 寻求解决额外验证性证据要求的可行路径
美股速递 · 02-11
Outlook Therapeutics Inc:拟继续与FDA合作 寻求解决额外验证性证据要求的可行路径
Outlook Therapeutics, Inc.盘中异动 早盘急速下跌5.11%
市场透视 · 01-15
Outlook Therapeutics, Inc.盘中异动 早盘急速下跌5.11%
Outlook Therapeutics任命Laura Cantrell为战略规划与业务拓展副总裁
美股速递 · 01-06
Outlook Therapeutics任命Laura Cantrell为战略规划与业务拓展副总裁
Outlook Therapeutics公司:FDA尚未明确何种验证性证据可被接受
美股速递 · 01-01
Outlook Therapeutics公司:FDA尚未明确何种验证性证据可被接受
Outlook Therapeutics公布美国FDA对湿性AMD治疗药物Ons-5010/Lytenava™(贝伐珠单抗-Vikg)审评的最新监管进展
美股速递 · 01-01
Outlook Therapeutics公布美国FDA对湿性AMD治疗药物Ons-5010/Lytenava™(贝伐珠单抗-Vikg)审评的最新监管进展
Outlook Therapeutics Inc:Ons-5010如获批准,将以Lytenava品牌用于湿性年龄相关性黄斑变性治疗
美股速递 · 2025-11-13
Outlook Therapeutics Inc:Ons-5010如获批准,将以Lytenava品牌用于湿性年龄相关性黄斑变性治疗
FDA拒绝批准眼部疾病药物后,Outlook Therapeutics, Inc.股价盘前暴跌60.4%
美股速递 · 2025-08-28
FDA拒绝批准眼部疾病药物后,Outlook Therapeutics, Inc.股价盘前暴跌60.4%
Outlook Therapeutics:FDA建议为Ons-5010申请提交确认性疗效证据
美股速递 · 2025-08-28
Outlook Therapeutics:FDA建议为Ons-5010申请提交确认性疗效证据
Outlook Therapeutics就FDA审查Ons-5010/Lytenava™(Bevacizumab-Vikg)湿性AMD治疗药物提供监管进展更新
美股速递 · 2025-08-28
Outlook Therapeutics就FDA审查Ons-5010/Lytenava™(Bevacizumab-Vikg)湿性AMD治疗药物提供监管进展更新
Outlook Therapeutics, Inc.盘中异动 下午盘股价大跌5.34%报1.41美元
市场透视 · 2025-03-11
Outlook Therapeutics, Inc.盘中异动 下午盘股价大跌5.34%报1.41美元
Outlook Therapeutics, Inc.盘中异动 下午盘股价大涨5.28%报1.50美元
市场透视 · 2025-03-05
Outlook Therapeutics, Inc.盘中异动 下午盘股价大涨5.28%报1.50美元
Outlook Therapeutics, Inc.盘中异动 下午盘股价大跌5.00%报1.43美元
市场透视 · 2025-03-04
Outlook Therapeutics, Inc.盘中异动 下午盘股价大跌5.00%报1.43美元
Outlook Therapeutics, Inc.盘中异动 早盘快速拉升5.80%
市场透视 · 2025-02-28
Outlook Therapeutics, Inc.盘中异动 早盘快速拉升5.80%
Outlook Therapeutics, Inc.盘中异动 下午盘股价大跌5.23%报1.44美元
市场透视 · 2025-02-26
Outlook Therapeutics, Inc.盘中异动 下午盘股价大跌5.23%报1.44美元
Outlook Therapeutics, Inc.盘中异动 股价大跌5.43%
市场透视 · 2025-02-22
Outlook Therapeutics, Inc.盘中异动 股价大跌5.43%
Outlook Therapeutics, Inc.盘中异动 股价大跌5.35%报1.77美元
市场透视 · 2025-02-18
Outlook Therapeutics, Inc.盘中异动 股价大跌5.35%报1.77美元
Outlook Therapeutics, Inc.盘中异动 临近收盘快速上涨5.17%报1.83美元
市场透视 · 2025-02-14
Outlook Therapeutics, Inc.盘中异动 临近收盘快速上涨5.17%报1.83美元
Outlook Therapeutics, Inc.盘中异动 股价大跌5.33%报1.60美元
市场透视 · 2025-02-12
Outlook Therapeutics, Inc.盘中异动 股价大跌5.33%报1.60美元
Outlook Therapeutics, Inc.盘中异动 快速下挫5.26%报1.62美元
市场透视 · 2025-02-11
Outlook Therapeutics, Inc.盘中异动 快速下挫5.26%报1.62美元
{"stockData":{"symbol":"OTLK","market":"US","secType":"STK","nameCN":"Outlook Therapeutics, Inc.","latestPrice":0.4096,"timestamp":1771448400000,"preClose":0.4223,"halted":0,"volume":1258017,"hourTrading":{"tag":"盘后","latestPrice":0.4112,"preClose":0.4096,"latestTime":"17:00 EST","volume":6896,"amount":2830.38334432,"timestamp":1771452012193,"change":0.0016,"changeRate":0.003906,"amplitude":0.008301},"delay":0,"changeRate":-0.03007340753019178,"floatShares":58175400,"shares":73509500,"eps":-1.794017,"marketStatus":"盘后交易","change":-0.0127,"latestTime":"02-18 17:00:13 EST","open":0.4266,"high":0.4266,"low":0.39,"amount":510218.45839086,"amplitude":0.086668,"askPrice":0.4483,"askSize":100,"bidPrice":0.4112,"bidSize":1947,"shortable":0,"etf":0,"ttmEps":-1.794017,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1771462800000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.4223,"preHourTrading":{"tag":"盘前","latestPrice":0.4253,"preClose":0.4223,"latestTime":"09:05 EST","volume":3253,"amount":1384.85632751,"timestamp":1771423511527,"change":0.003,"changeRate":0.007104,"amplitude":0.017997},"postHourTrading":{"tag":"盘后","latestPrice":0.4112,"preClose":0.4096,"latestTime":"17:00 EST","volume":6896,"amount":2830.38334432,"timestamp":1771452012193,"change":0.0016,"changeRate":0.003906,"amplitude":0.008301},"volumeRatio":0.588682,"impliedVol":2.2354,"impliedVolPercentile":0.757},"requestUrl":"/m/hq/s/OTLK/wiki","defaultTab":"wiki","newsList":[{"id":"2612978184","title":"Outlook Therapeutics, Inc.盘中异动 股价大跌5.78%报0.462美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2612978184","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612978184?lang=zh_cn&edition=full","pubTime":"2026-02-17 22:30","pubTimestamp":1771338641,"startTime":"0","endTime":"0","summary":"北京时间2026年02月17日22时30分,Outlook Therapeutics, Inc.股票出现异动,股价快速下挫5.78%。Outlook Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.00%。其相关个股中,Polaryx Therapeutics, Inc.、Ernexa Therapeutics Inc.、Kalaris Therapeutics, Inc.涨幅较大,Ernexa Therapeutics Inc.、Polaryx Therapeutics, Inc.、Quince Therapeutics, Inc.较为活跃,换手率分别为60.99%、26.50%、26.09%,振幅较大的相关个股有Alpha Cognition Inc.、Igc Pharma, Inc.、Onconetix, Inc.,振幅分别为10.41%、10.12%、6.97%。Outlook Therapeutics, Inc.公司简介:Outlook Therapeutics Inc是一家临床阶段生物制药公司,专注于开发和商业化ONS-5010,这是一种用于各种眼科适应症的单克隆抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260217223041a4ad855c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260217223041a4ad855c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4007","BK4139","OTLK","LENZ"],"gpt_icon":0},{"id":"1145450453","title":"Outlook Therapeutics Inc:拟继续与FDA合作 寻求解决额外验证性证据要求的可行路径","url":"https://stock-news.laohu8.com/highlight/detail?id=1145450453","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145450453?lang=zh_cn&edition=full","pubTime":"2026-02-11 21:50","pubTimestamp":1770817840,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Inc表示,计划继续与美国食品药品监督管理局(FDA)保持密切合作,共同探索可行路径,以解决FDA提出的关于补充提供额外验证性证据的要求。公司致力于推进相关程序,确保符合监管标准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2603364809","title":"Outlook Therapeutics, Inc.盘中异动 早盘急速下跌5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603364809","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603364809?lang=zh_cn&edition=full","pubTime":"2026-01-15 22:37","pubTimestamp":1768487871,"startTime":"0","endTime":"0","summary":"北京时间2026年01月15日22时37分,Outlook Therapeutics, Inc.股票出现异动,股价急速跳水5.11%。Outlook Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.34%。其相关个股中,Cns Pharmaceuticals, Inc.、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Immunitybio, Inc.涨幅较大,Gt Biopharma, Inc.、Applied Therapeutics, Inc.、Genprex, Inc.较为活跃,换手率分别为50.97%、42.84%、20.56%,振幅较大的相关个股有Briacell Therapeutics Corp C/Wts 、60 Degrees Pharmaceuticals, Inc.、Cns Pharmaceuticals, Inc.,振幅分别为64.67%、21.43%、15.65%。Outlook Therapeutics, Inc.公司简介:Outlook Therapeutics Inc是一家临床阶段生物制药公司,专注于开发和商业化ONS-5010,这是一种用于各种眼科适应症的单克隆抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115223751a4c81db0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115223751a4c81db0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","LENZ","OTLK","BK4139","BK4007"],"gpt_icon":0},{"id":"1141589852","title":"Outlook Therapeutics任命Laura Cantrell为战略规划与业务拓展副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=1141589852","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141589852?lang=zh_cn&edition=full","pubTime":"2026-01-06 21:36","pubTimestamp":1767706580,"startTime":"0","endTime":"0","summary":"生物制药公司Outlook Therapeutics, Inc.近日宣布一项重要人事任命——Laura Cantrell正式加入公司管理层,担任企业战略与业务发展副总裁一职。此次任命将强化公司在眼科生物制剂领域的战略布局,Cantrell女士将主导全球商业合作机会的挖掘与战略规划体系的优化。首席执行官Russell Trenary表示:\"Laura在生物制药商业拓展领域的卓越履历,与公司现阶段发展需求高度契合。\"据悉,Cantrell将直接向Trenary汇报工作,并参与制定公司长期发展战略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"1195317623","title":"Outlook Therapeutics公司:FDA尚未明确何种验证性证据可被接受","url":"https://stock-news.laohu8.com/highlight/detail?id=1195317623","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195317623?lang=zh_cn&edition=full","pubTime":"2026-01-01 05:17","pubTimestamp":1767215830,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics公司近日面临监管不确定性,美国食品药品监督管理局(FDA)至今未就公司提交的药品申请给出明确指引。监管机构尚未表态何种类型的验证性临床证据能够满足审批要求,这为该公司核心产品的上市路径增添了变数。\n当前局面反映出生物科技企业在创新药审评过程中常见的挑战。FDA的沉默意味着Outlook Therapeutics需要继续投入资源探索符合监管要求的证据体系,而这一过程可能影响产品商业化的时间表。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"1145824968","title":"Outlook Therapeutics公布美国FDA对湿性AMD治疗药物Ons-5010/Lytenava™(贝伐珠单抗-Vikg)审评的最新监管进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1145824968","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145824968?lang=zh_cn&edition=full","pubTime":"2026-01-01 05:16","pubTimestamp":1767215790,"startTime":"0","endTime":"0","summary":"生物制药公司Outlook Therapeutics, Inc. (OTLK) 近日披露了旗下核心产品Ons-5010/Lytenava™(贝伐珠单抗-Vikg)针对湿性年龄相关性黄斑变性(湿性AMD)适应症的最新监管动态。该公司已接获美国食品药品监督管理局(FDA)就该项新药申请(BLA)的审评更新通知,标志着该疗法在美获批进程中迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"1174726101","title":"Outlook Therapeutics Inc:Ons-5010如获批准,将以Lytenava品牌用于湿性年龄相关性黄斑变性治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1174726101","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174726101?lang=zh_cn&edition=full","pubTime":"2025-11-13 21:31","pubTimestamp":1763040691,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Inc:Ons-5010如获批准,将以Lytenava品牌用于湿性年龄相关性黄斑变性治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"1137059470","title":"FDA拒绝批准眼部疾病药物后,Outlook Therapeutics, Inc.股价盘前暴跌60.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1137059470","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137059470?lang=zh_cn&edition=full","pubTime":"2025-08-28 18:35","pubTimestamp":1756377317,"startTime":"0","endTime":"0","summary":"FDA拒绝批准眼部疾病药物后,Outlook Therapeutics, Inc.股价盘前暴跌60.4%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"1151455951","title":"Outlook Therapeutics:FDA建议为Ons-5010申请提交确认性疗效证据","url":"https://stock-news.laohu8.com/highlight/detail?id=1151455951","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151455951?lang=zh_cn&edition=full","pubTime":"2025-08-28 18:32","pubTimestamp":1756377134,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics表示,美国食品药品监督管理局(FDA)建议该公司提交确认性疗效证据,以支持其Ons-5010产品的申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"1155673207","title":"Outlook Therapeutics就FDA审查Ons-5010/Lytenava™(Bevacizumab-Vikg)湿性AMD治疗药物提供监管进展更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1155673207","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155673207?lang=zh_cn&edition=full","pubTime":"2025-08-28 18:30","pubTimestamp":1756377034,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics就美国食品药品监督管理局审查其Ons-5010/Lytenava™(Bevacizumab-Vikg)湿性年龄相关性黄斑变性治疗药物的情况提供了监管进展更新。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2518042662","title":"Outlook Therapeutics, Inc.盘中异动 下午盘股价大跌5.34%报1.41美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518042662","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518042662?lang=zh_cn&edition=full","pubTime":"2025-03-11 02:56","pubTimestamp":1741633004,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日02时56分,Outlook Therapeutics, Inc.股票出现异动,股价急速下跌5.34%。Outlook Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.47%。其相关个股中,Aeon Biopharma, Inc.、Mineralys Therapeutics, Inc.、Checkpoint Therapeutics, Inc.涨幅较大,Aeon Biopharma, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.较为活跃,换手率分别为6148.90%、3854.04%、1014.79%,振幅较大的相关个股有Aeon Biopharma, Inc.、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Biodexa Pharmaceuticals Plc,振幅分别为90.44%、88.14%、59.34%。Outlook Therapeutics, Inc.公司简介:Outlook Therapeutics Inc 是一家临床阶段生物制药公司,专注于开发和商业化 ONS-5010,这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311025644a26a9d94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311025644a26a9d94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OTLK","BK4139","LENZ"],"gpt_icon":0},{"id":"2517698565","title":"Outlook Therapeutics, Inc.盘中异动 下午盘股价大涨5.28%报1.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517698565","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517698565?lang=zh_cn&edition=full","pubTime":"2025-03-05 04:19","pubTimestamp":1741119563,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日04时19分,Outlook Therapeutics, Inc.股票出现异动,股价急速上涨5.28%。Outlook Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.09%。Outlook Therapeutics, Inc.公司简介:Outlook Therapeutics Inc 是一家临床阶段生物制药公司,专注于开发和商业化 ONS-5010,这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305041923a25f65a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305041923a25f65a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OTLK","BK4139","LENZ"],"gpt_icon":0},{"id":"2516688296","title":"Outlook Therapeutics, Inc.盘中异动 下午盘股价大跌5.00%报1.43美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516688296","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516688296?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:02","pubTimestamp":1741032163,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时02分,Outlook Therapeutics, Inc.股票出现异动,股价大幅跳水5.00%。Outlook Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.20%。其相关个股中,Bioxcel Therapeutics, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Biocardia, Inc.涨幅较大,Bioxcel Therapeutics, Inc.、Allarity Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃,换手率分别为4576.31%、211.77%、182.41%,振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.,振幅分别为206.20%、119.50%、70.53%。Outlook Therapeutics, Inc.公司简介:Outlook Therapeutics Inc 是一家临床阶段生物制药公司,专注于开发和商业化 ONS-5010,这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304040243abe68edc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304040243abe68edc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","OTLK","BK4139"],"gpt_icon":0},{"id":"2514566375","title":"Outlook Therapeutics, Inc.盘中异动 早盘快速拉升5.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514566375","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514566375?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:53","pubTimestamp":1740754380,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时53分,Outlook Therapeutics, Inc.股票出现异动,股价急速上涨5.80%。Outlook Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.28%。Outlook Therapeutics, Inc.公司简介:Outlook Therapeutics Inc 是一家临床阶段生物制药公司,专注于开发和商业化 ONS-5010,这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228225300abe0f06f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228225300abe0f06f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","OTLK"],"gpt_icon":0},{"id":"2514045867","title":"Outlook Therapeutics, Inc.盘中异动 下午盘股价大跌5.23%报1.44美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514045867","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514045867?lang=zh_cn&edition=full","pubTime":"2025-02-26 03:28","pubTimestamp":1740511706,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日03时28分,Outlook Therapeutics, Inc.股票出现波动,股价急速跳水5.23%。Outlook Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.18%。Outlook Therapeutics, Inc.公司简介:Outlook Therapeutics Inc 是一家临床阶段生物制药公司,专注于开发和商业化 ONS-5010,这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226032826abdcc28f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226032826abdcc28f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","OTLK","LENZ"],"gpt_icon":0},{"id":"2513214988","title":"Outlook Therapeutics, Inc.盘中异动 股价大跌5.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513214988","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513214988?lang=zh_cn&edition=full","pubTime":"2025-02-22 04:07","pubTimestamp":1740168426,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日04时07分,Outlook Therapeutics, Inc.股票出现异动,股价急速下挫5.43%。Outlook Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.48%。其相关个股中,Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Invivyd, Inc.、Moolec Science Sa C/Wts 涨幅较大,Aditxt, Inc.、Nkgen Biotech, Inc.、Osr Holdings, Inc.较为活跃,换手率分别为316.92%、251.10%、138.24%,振幅较大的相关个股有Osr Holdings, Inc.、Invivyd, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028,振幅分别为76.52%、70.25%、61.26%。Outlook Therapeutics, Inc.公司简介:Outlook Therapeutics Inc 是一家临床阶段生物制药公司,专注于开发和商业化 ONS-5010,这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222040707a24ef57e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222040707a24ef57e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","OTLK"],"gpt_icon":0},{"id":"2512166707","title":"Outlook Therapeutics, Inc.盘中异动 股价大跌5.35%报1.77美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512166707","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512166707?lang=zh_cn&edition=full","pubTime":"2025-02-18 23:01","pubTimestamp":1739890874,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日23时01分,Outlook Therapeutics, Inc.股票出现异动,股价急速下挫5.35%。Outlook Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.52%。Outlook Therapeutics, Inc.公司简介:Outlook Therapeutics Inc 是一家临床阶段生物制药公司,专注于开发和商业化 ONS-5010,这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218230114abd3b5ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218230114abd3b5ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OTLK","LENZ","BK4139"],"gpt_icon":0},{"id":"2511257095","title":"Outlook Therapeutics, Inc.盘中异动 临近收盘快速上涨5.17%报1.83美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511257095","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511257095?lang=zh_cn&edition=full","pubTime":"2025-02-14 04:50","pubTimestamp":1739479816,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日04时50分,Outlook Therapeutics, Inc.股票出现波动,股价急速拉升5.17%。Outlook Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为1.18%。其相关个股中,Moleculin Biotech, Inc.、Dominari Holdings Inc.、Edesa Biotech, Inc.涨幅较大,Edesa Biotech, Inc.、Moleculin Biotech, Inc.、Tc Biopharm Plc较为活跃,换手率分别为3288.28%、2317.46%、1269.38%,振幅较大的相关个股有Moleculin Biotech, Inc.、Edesa Biotech, Inc.、Immatics N V C/Wts 01/07/2025 ,振幅分别为733.31%、95.15%、92.30%。Outlook Therapeutics, Inc.公司简介:Outlook Therapeutics Inc 是一家临床阶段生物制药公司,专注于开发和商业化 ONS-5010,这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214045016988475bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214045016988475bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","OTLK","BK4139"],"gpt_icon":0},{"id":"2510332620","title":"Outlook Therapeutics, Inc.盘中异动 股价大跌5.33%报1.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510332620","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510332620?lang=zh_cn&edition=full","pubTime":"2025-02-12 01:05","pubTimestamp":1739293558,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日01时05分,Outlook Therapeutics, Inc.股票出现异动,股价大幅下跌5.33%。Outlook Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为1.74%。其相关个股中,Omega Therapeutics, Inc.、Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.涨幅较大,Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃,换手率分别为3014.30%、1344.27%、439.69%,振幅较大的相关个股有Omega Therapeutics, Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.,振幅分别为143.33%、59.46%、58.60%。Outlook Therapeutics, Inc.公司简介:Outlook Therapeutics Inc 是一家临床阶段生物制药公司,专注于开发和商业化 ONS-5010,这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502120105589881d747&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502120105589881d747&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","OTLK"],"gpt_icon":0},{"id":"2510894173","title":"Outlook Therapeutics, Inc.盘中异动 快速下挫5.26%报1.62美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510894173","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510894173?lang=zh_cn&edition=full","pubTime":"2025-02-11 04:04","pubTimestamp":1739217899,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日04时04分,Outlook Therapeutics, Inc.股票出现波动,股价急速下跌5.26%。Outlook Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.95%。Outlook Therapeutics, Inc.公司简介:Outlook Therapeutics Inc 是一家临床阶段生物制药公司,专注于开发和商业化 ONS-5010,这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502110404599880b79d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502110404599880b79d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","OTLK","BK4139"],"gpt_icon":0}],"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Outlook Therapeutics, Inc.(OTLK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Outlook Therapeutics, Inc.(OTLK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Outlook Therapeutics, Inc.,OTLK,Outlook Therapeutics, Inc.股票,Outlook Therapeutics, Inc.股票老虎,Outlook Therapeutics, Inc.股票老虎国际,Outlook Therapeutics, Inc.行情,Outlook Therapeutics, Inc.股票行情,Outlook Therapeutics, Inc.股价,Outlook Therapeutics, Inc.股市,Outlook Therapeutics, Inc.股票价格,Outlook Therapeutics, Inc.股票交易,Outlook Therapeutics, Inc.股票购买,Outlook Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Outlook Therapeutics, Inc.(OTLK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Outlook Therapeutics, Inc.(OTLK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}